Skip to main
DCGO

DocGo (DCGO) Stock Forecast & Price Target

DocGo (DCGO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

DocGo is expected to experience strong growth in its Medical Mobility revenue due to the expansion into new markets and its integration of a logistics platform and lower-cost staffing model. While 2026 has been a transition year for the company, it is expected to see mid-teens-plus earnings growth in the future. Recent acquisitions, such as SteadyMD, have also shown promising growth and could be a potential white-label clinical back-end for other healthcare companies. Despite the current stock trading below its net cash value, the company is making progress in repositioning itself for future growth.

Bears say

DocGo is facing several challenges in its quest for profitability and sustainable growth. While the company's revenue has exceeded expectations in the most recent quarter, the increase was largely due to contributions from sunsetting migrant-related contracts, indicating a decline in organic non-migrant Mobile Health revenue. Additionally, the company's cost structure needs to be optimized to achieve its targeted adj-EBITDA profitability in 2026. The ongoing COVID-related uncertainty, with a potential decline in testing revenue in the future, also poses a risk for the company's financials. Despite the potential positive outcome from its exploration of strategic alternatives, it may take some time for investors to feel comfortable with the durability of DocGo's revenue stream, leading to a discounted valuation.

DocGo (DCGO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DocGo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DocGo (DCGO) Forecast

Analysts have given DocGo (DCGO) a Buy based on their latest research and market trends.

According to 4 analysts, DocGo (DCGO) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DocGo (DCGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.